This eXtract video features key information from the 61st American Society of Hematology (ASH) Annual Meeting & Exposition. This quick tour with an expert focuses on data presented from the ELEVATE-TN trial. In the front-line setting, newly presented data associated a novel selective BTK inhibitor with the greatest protection against progression or death so far observed relative to a chemotherapy-containing regimen.

Approximately 10% of all primary care visits involve dermatologic conditions. Of these complaints, atopic dermatitis, urticaria, impetigo, rosacea, and psoriasis are among the most common. In this program, the key features of these diseases, all of which are typically diagnosed on the basis of history and physical examination alone, are summarized and compared. For patients who do not respond to well-defined first-line therapies, specialist referrals are appropriate, but early recognition and stepwise treatment at the level of primary care is sufficient to control symptoms in most individuals for all five conditions.

This eXtract video features key information from the American Society of Nephrology (ASN) Kidney Week 2019. This quick tour with an expert focuses on data presented from the OLYMPUS, ROCKIES and HIMALAYAS trials. In patients with chronic kidney disease (CKD) or on dialysis, a novel therapy is poised to reorder treatment options for anemia, according to the data presented from these global phase 3 studies.

This eXtract video features key information from the American Heart Association (AHA) 2019 Scientific Sessions. This quick tour with an expert focuses on data presented on the primary TWILIGHT study and ACS subgroup analysis. The results show that following a high-risk PCI, withdrawal of aspirin while continuing ticagrelor monotherapy, resulted in a significant reduction of major bleeding risk without compromising ischemic benefit.

This eXtract video features key information from the 2019 American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting. This quick tour with an expert focuses on 48-week data presented from the SELECT-COMPARE trial. These data confirm the safety and efficacy of a small molecule JAK inhibitor to treat patients with moderate to severe rheumatoid arthritis.

The measles/mumps/rubella (MMR) vaccine has been available in Canada since the 1970s and routine vaccination has reduced the incidence of these diseases by 99%. The MMR vaccine is also available in combination with varicella (MMRV). However, not all children are receiving these vaccines, despite the fact that these diseases can cause serious morbidity and even mortality. This program will review the diseases, the vaccines that prevent them, describe vaccine hesitancy and provide tips and tricks on how to educate parents on the importance of these vaccines.

In the 1980s, inhaled corticosteroids (ICS) were adopted for use in chronic obstructive pulmonary disease (COPD) on the basis of their effectiveness in asthma, rather than on scientific evidence. In fact, evidence supporting their use in COPD is equivocal and their positioning in guidelines controversial. Despite this, evidence shows that ICS are being over-prescribed when they are not recommended. This program will review treatment objectives, the evidence and myths surrounding the use of ICS in COPD, better define which patients may benefit from ICS-containing therapy, and refocus on individualized treatment regimens.

This eXtract video features key information on shingles, the associated patient burden, available herpes zoster (HZ) vaccines as well as the NACI 2018 recommendations regarding the use of these vaccines. While there are available vaccines to prevent the occurrence of HZ, some still refuse immunization. Recommendations from health care providers are pivotal in the effort to build confidence in immunization against vaccine preventable diseases.

This eXtract video features key information from the 2019 Congress of the European Society for Medical Oncology (ESMO). This quick tour with an expert focuses on final overall survival data presented from the FLAURA trial. These data have established a new treatment standard in EGFR mutation-positive NSCLC.

This eXtract video features key information from the 29th International Congress of the European Respiratory Society (ERS). This quick tour with an expert focuses on real-world data presented from the STELLAIR study.